Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Kyowa Kirin Co., Ltd.

https://www.kyowakirin.com/

Latest From Kyowa Kirin Co., Ltd.

Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions

Bookmark
  • Analysis
By Lisa Takagi

Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI  reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.

Japan Approvals

Japan Approves Leqembi, All Eyes Now On Extended Pricing Discussions

Bookmark
  • Analysis
By Lisa Takagi

Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI  reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.

Japan Approvals

Japan Sets Luxturna, Other New Prices While Cutting Selected Fast Growers

Bookmark
  • Analysis
By Lisa Takagi

Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.

Japan Regenerative Medicine

Deal Watch: Novartis, Ionis Team Up Again In Cardiovascular Disease

Bookmark
  • News
By Joseph Haas

Plus deals involving ProQR/ Thea, Aeglea/Immedica, Ayala/Biolight, Quince/EryDel, ImmunoBiochem/ImmunoGen and GSK/LimmaTech, as well as deals in brief.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Pharmaceuticals
    • Nutraceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Archimedes Pharma Ltd.
    • Centus Biotherapeutics Ltd.
    • Daiichi Fine Chemical Co., Ltd.
    • Fujifilm Kyowa Kirin Biologics Co., Ltd.
    • Kirin Pharma Company, Limited
    • Kyowa Kirin Asia Pacific Pte. Ltd.
    • Kyowa Kirin Australia Pty Ltd
    • Kyowa Kirin International PLC
    • Kyowa Pharma Chemical Co., Ltd.
    • ProStrakan Group plc
    • Kyowa Kirin
    • Kyowa Kirin Frontier Co., Ltd.
    • Kyowa Hakko Kirin (Singapore) Pte. Ltd.
    • Kyowa Hakko Kirin Co., Ltd.
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By